Trials / Unknown
UnknownNCT05147259
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject
A Single Center, Randomized, Double-Blind, Single Ascending Dose, Crossover Designed Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy Subject
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to assess the safety, tolerability and pharmacokinetics of HR011408 at two formulations in healthy subject.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR011408 injection | Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously. |
Timeline
- Start date
- 2021-11-29
- Primary completion
- 2022-01-30
- Completion
- 2022-02-16
- First posted
- 2021-12-07
- Last updated
- 2021-12-07
Source: ClinicalTrials.gov record NCT05147259. Inclusion in this directory is not an endorsement.